Pfizer added to Depo-Provera meningioma claim in Washington court

By AI, Created 9:21 PM UTC, June 03, 2026, /AGP/ – A Clark County, Washington, lawsuit names Pfizer in a claim that Depo-Provera contributed to the growth of a meningioma and led to a craniotomy. The filing also says the drug was continued after the diagnosis, raising questions about warning duties and prescribing decisions.

Why it matters: - The claim adds Pfizer to litigation tied to Depo-Provera and alleged meningioma growth. - The case centers on whether earlier warnings could have changed prescribing decisions and reduced harm. - The alleged outcome included brain surgery, raising the stakes for patients, prescribers and drug makers.

What happened: - A plaintiff in Clark County, Washington, is bringing a claim over Depo-Provera use before and after a meningioma diagnosis. - The filing says Depo-Provera caused the tumor to grow and that a craniotomy became necessary. - Pfizer is named as a defendant in the claim. - The case number is 25-2-04507-06.

The details: - Dr. Greg Vigna said Pfizer had reason by 2018 to issue a Dear Doctor Letter warning about meningioma growth and recurrence tied to continued Depo-Provera use. - The filing says that warning was not issued. - Dr. Vigna said Depo-Provera may be associated with an increased risk of meningioma. - Dr. Vigna also said that risk might have been avoided through traditional birth control pills. - The claim also names the prescribing physician for continuing the drug after the meningioma diagnosis was known. - The attorneys involved represent women who have suffered meningiomas.

Between the lines: - The case points to two potential fault lines: drug labeling or warning timing, and prescribing decisions after diagnosis. - If the allegations hold, the dispute could influence how physicians think about Depo-Provera use in patients with tumor risk concerns. - The filing also reflects broader litigation pressure on manufacturers over alleged failure to warn.

What’s next: - The case will move forward through litigation in Washington state court. - More filings could clarify the evidence around causation, warnings and the timing of the diagnosis. - Dr. Vigna directed viewers to educational content on Depo-Provera and meningioma risk, including more information.

The bottom line: - Pfizer now faces a claim that Depo-Provera was linked to tumor growth after diagnosis and that earlier warnings might have changed the outcome.